GLAXF Stock Financial Analysis - GSK plc (OTCPK) Stock

Overview

GSK plc, based in the United Kingdom, is a global healthcare company primarily engaged in the development, manufacturing, and marketing of pharmaceuticals, vaccines, and consumer healthcare products. The company operates through three primary segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Key initiatives include a robust focus on respiratory diseases, HIV, oncology, and immuno-inflammation with an increasing investment in advanced technologies and R&D to drive biopharmaceutical innovations. GSK is also deeply involved in extensive vaccine research and development, targeting a broad range of infectious diseases that include influenza, herpes zoster, and COVID-19. Moreover, GSK's Consumer Healthcare segment works on improving everyday health through products in oral health, pain relief, cold, flu and allergy, digestion, and nutrition.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for GSK plc as of June 30, 2025 is 31,631.00 MM.
The operating income for GSK plc as of June 30, 2025 is 6,368.00 MM.
The net income for GSK plc as of June 30, 2025 is 3,423.00 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	31,631.00	6,368.00	3,423.00
2025-03-31	31,529.00	6,251.00	3,153.00
2024-12-31	31,376.00	6,184.00	2,575.00
2024-09-30	31,311.00	6,935.00	2,511.00
2024-06-30	31,446.00	9,033.00	4,033.00
2024-03-31	30,740.00	8,727.00	4,484.00
2023-12-31	30,328.00	8,403.00	4,928.00
2023-09-30	29,652.00	7,597.00	6,073.00
2023-06-30	29,334.00	7,842.00	15,430.00
2023-03-31	29,085.00	7,426.00	14,644.00
2022-12-31	29,324.00	7,322.00	14,956.00
2022-09-30	29,024.00	7,489.00	14,210.00
2022-06-30	27,822.00	6,412.00	4,557.00
2022-03-31	26,731.00	6,296.00	5,114.00
2021-12-31	24,696.00	5,634.00	4,385.00
2021-09-30	26,359.00	6,557.00	4,313.00
2021-06-30	28,378.00	7,132.00	4,389.00
2021-03-31	30,164.00	7,212.00	5,257.00
2020-12-31	24,354.00	6,050.00	5,749.00
2020-09-30	34,259.00	8,628.00	6,371.00
2020-06-30
2020-03-31

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31	0.63	0.62
2024-09-30	0.62	0.61
2024-06-30	0.99	0.98
2024-03-31	1.10	1.09
2023-12-31	1.22	1.20
2023-09-30	1.50	1.48
2023-06-30	3.82	3.76
2023-03-31	3.63	3.58
2022-12-31	3.71	3.66
2022-09-30	3.53	3.48
2022-06-30	1.14	1.12
2022-03-31	1.28	1.26
2021-12-31	1.10	1.08
2021-09-30	1.08	1.07
2021-06-30	1.10	1.09
2021-03-31	1.32	1.30
2020-12-31	1.44	1.43
2020-09-30	1.60	1.58
2020-06-30	1.68	1.66
2020-03-31	1.36	1.34

Cash Flow: Operations, Investing, Financing

The cash from operating activities for GSK plc as of June 30, 2025 is 7,724.00 MM.
The cash from investing activities for GSK plc as of June 30, 2025 is -3,619.00 MM.
The cash from financing activities for GSK plc as of June 30, 2025 is -3,596.00 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	7,724.00	-3,619.00	-3,596.00
2025-03-31	6,741.00	-2,224.00	-2,808.00
2024-12-31	6,554.00	-1,229.00	-4,726.00
2024-09-30	7,421.00	158.00	-7,476.00
2024-06-30	7,479.00	398.00	-7,998.00
2024-03-31	7,673.00	-1,336.00	-6,383.00
2023-12-31	6,768.00	-1,595.00	-5,641.00
2023-09-30	5,477.00	-2,403.00	-3,387.00
2023-06-30	4,586.00	-6,006.00	-2,951.00
2023-03-31	4,914.00	-5,587.00	-7,468.00
2022-12-31	7,403.00	-8,772.00	823.00
2022-09-30	9,265.00	-8,593.00	-613.00
2022-06-30	10,506.00	-5,682.00	-681.00
2022-03-31	10,163.00	-5,322.00	1,760.00
2021-12-31	7,952.00	-1,777.00	-7,589.00
2021-09-30	8,040.00	-1,468.00	-6,990.00
2021-06-30	6,339.00	-845.00	-9,872.00
2021-03-31	7,807.00	2,171.00	-10,456.00
2020-12-31	8,441.00	2,161.00	-10,132.00
2020-09-30	8,039.00	1,843.00	-10,716.00
2020-06-30
2020-03-31

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Management Effectiveness

The roa for GSK plc as of June 30, 2025 is 0.05.
The roe for GSK plc as of June 30, 2025 is 0.23.
The roic for GSK plc as of June 30, 2025 is 0.09.
The croic for GSK plc as of June 30, 2025 is 0.05.
The ocroic for GSK plc as of June 30, 2025 is 0.19.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	0.05	0.23	0.09	0.05	0.19
2025-03-31	0.04	0.19	0.08	0.02	0.20
2024-12-31	0.04	0.20	0.09	0.00	0.25
2024-09-30	0.07	0.32	0.13	-0.01	0.24
2024-06-30	0.08	0.40	0.14	-0.00	0.24
2024-03-31	0.08	0.49	0.15	-0.02	0.21
2023-12-31			0.48	-0.03
2023-09-30			1.27	-0.36
2023-06-30	0.00	0.68	1.17	-0.33
2023-03-31		0.65	1.19	-0.65
2022-12-31
2022-09-30		0.00
2022-06-30		0.21	0.20
2022-03-31		0.00
2021-12-31		0.21
2021-09-30	0.05	0.21
2021-06-30	0.05		0.09	-0.09	0.13
2021-03-31	0.06	0.26	0.10	-0.01	0.15
2020-12-31	0.07	0.31	0.11	0.01	0.16
2020-09-30	0.08	0.35	0.13	-0.02	0.16
2020-06-30	0.10	2.25	0.13	0.06	0.18
2020-03-31	0.09	1.60	0.10	0.01	0.16

Gross Margins

The gross margin for GSK plc as of June 30, 2025 is 0.72.
The net margin for GSK plc as of June 30, 2025 is 0.10.
The operating margin for GSK plc as of June 30, 2025 is 0.20.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.72	0.10	0.20
2025-03-31	0.72	0.08	0.21
2024-12-31	0.72	0.08	0.22
2024-09-30	0.73	0.13	0.29
2024-06-30	0.73	0.15	0.28
2024-03-31	0.72	0.16	0.26
2023-12-31		0.20	0.26
2023-09-30		0.53	0.27
2023-06-30		0.53	0.27
2023-03-31		0.50	0.25
2022-12-31
2022-09-30		0.00	0.00
2022-06-30		0.12	0.23
2022-03-31
2021-12-31
2021-09-30
2021-06-30	0.68	0.13	0.25
2021-03-31	0.67	0.16	0.24
2020-12-31	0.68	0.17	0.24
2020-09-30	0.68	0.19	0.25
2020-06-30	0.68	0.19	0.25
2020-03-31	0.68	0.15	0.26

DE:GS71	€16.95
MX:GSK1 N
GB:GSKL
GB:GSK	£1,476.00